Stock Research Monitor: JAGX, JAZZ, and LJPC
LONDON, UK / ACCESSWIRE / June 15, 2018 / If you want a free Stock Review on IOVA sign up now at www.wallstequities.com/registration. On Thursday, June 14, 2018, US markets saw five out of nine sectors finishing the day in green and four in red. Major US indices were also mixed at the close of yesterday's session. The NASDAQ Composite ended the day at 7,761.04, up 0.85%; the Dow Jones Industrial Average edged 0.10% lower, to finish at 25,175.31; and the S&P 500 closed at 2,782.49, up 0.25%. This Friday morning, WallStEquities.com looks at the performance of these four Biotechnology stocks: Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Jaguar Health Inc. (NASDAQ: JAGX), Jazz Pharmaceuticals PLC (NASDAQ: JAZZ), and La Jolla Pharmaceutical Co. (NASDAQ: LJPC). All you have to do is sign up today for this free limited time offer by clicking the link below.
On Thursday, shares in San Carlos, California headquartered Iovance Biotherapeutics Inc. recorded a trading volume of 919,495 shares, which was above their three months average volume of 879.91 thousand shares. The stock ended the session 2.24% lower at $13.10. The Company's shares have gained 116.53% in the past twelve months. The stock is trading above its 200-day moving average by 10.21%. Moreover, shares of Iovance Biotherapeutics, which focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells, have a Relative Strength Index (RSI) of 36.50. Get the full research report on IOVA for free by clicking below at:
San Francisco, California headquartered Jaguar Health Inc.'s stock closed the day 1.13% lower at $1.75 with a total trading volume of 73,618 shares. The stock is trading below its 50-day moving average by 25.44%. Additionally, shares of Jaguar Health, which focuses on developing gastrointestinal products for human prescription use and animals worldwide, have an RSI of 30.53. Free research on JAGX can be accessed at:
Shares in Dublin, Ireland headquartered Jazz Pharmaceuticals PLC recorded a trading volume of 406,247 shares. The stock ended yesterday's trading session 0.81% higher at $177.23. The Company's shares have advanced 19.19% over the previous three months and 17.20% in the past twelve months. The stock is trading above its 50-day and 200-day moving averages by 10.19% and 19.72%, respectively. Furthermore, shares of Jazz Pharma, which identifies, develops, and commercializes pharmaceutical products for various medical needs in the US, Europe, and internationally, have an RSI of 69.47. Sign up today for the free research report on JAZZ at:
La Jolla Pharmaceutical
San Diego, California headquartered La Jolla Pharmaceutical Co.'s stock finished Thursday's session 0.32% higher at $31.00 with a total trading volume of 247,252 shares. The Company's shares have advanced 11.31% in the past twelve months. The stock is trading below its 50-day moving average by 0.18%. Additionally, shares of La Jolla Pharma, which focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases, have an RSI of 47.14. Wall St. Equities' research coverage also includes the downloadable free report on LJPC at:
Wall St. Equities:
Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
WSE has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE: Wall St. Equities